Neurizon Therapeutics Ltd
Research Neurizon Therapeutics Ltd (NUZ) on Bullrun: market cap AUD 46.51M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerNUZ
- ExchangeAU
- CountryAustralia
- SectorHealthcare
- IndustryBiotechnology
- CurrencyAUD
- Market capAUD 46.51M
- Financial periodFY2025
- Net income-AUD 16.59M
- Free cash flow-AUD 14.29M
Valuation Snapshot
latest market cap is AUD 46.51M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | n/a | -AUD 16.59M | -AUD 14.29M | n/a | -0.03 | AUD 4.16M | n/a | AUD 2.82M |
| FY2024 | n/a | -AUD 7.67M | -AUD 5.17M | n/a | -0.02 | AUD 9.71M | n/a | AUD 10.23M |
| FY2023 | AUD 2.82M | -AUD 6.21M | -AUD 1.60M | 72.1% | -0.02 | AUD 2.71M | AUD 1.05M | AUD 3.89M |
| FY2022 | AUD 3.38M | -AUD 1.71M | -AUD 1.38M | 90.7% | -0.01 | AUD 2.42M | AUD 1.39M | AUD 7.84M |
| FY2021 | AUD 2.14M | n/a | n/a | 89.5% | n/a | n/a | AUD 1.28M | n/a |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-23 | AUD 46.51M | n/a | n/a | n/a |
About Neurizon Therapeutics Ltd
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Neurizon Therapeutics Ltd's market cap?
Neurizon Therapeutics Ltd's market capitalization is AUD 46.51M.
What does Neurizon Therapeutics Ltd do?
Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases. The company develops drug discovery intellectual property for the treatment of neurological diseases. Its lead candidate is NUZ-001, a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024.